Compare · IDXX vs QCLS
IDXX vs QCLS
Side-by-side comparison of IDEXX Laboratories Inc. (IDXX) and Q/C Technologies Inc. (QCLS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IDXX and QCLS operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- IDXX is the larger of the two at $43.33B, about 2168.3x QCLS ($20.0M).
- Over the past year, IDXX is down 14.2% and QCLS is down 68.4% - IDXX leads by 54.2 points.
- IDXX has been more active in the news (6 items in the past 4 weeks vs 3 for QCLS).
- IDXX has more recent analyst coverage (23 ratings vs 0 for QCLS).
- Company
- IDEXX Laboratories Inc.
- Q/C Technologies Inc.
- Price
- $550.27-1.71%
- $2.44+1.46%
- Market cap
- $43.33B
- $20.0M
- 1M return
- -1.10%
- -24.46%
- 1Y return
- -14.24%
- -68.43%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1991
- 2014
- News (4w)
- 6
- 3
- Recent ratings
- 23
- 0
IDEXX Laboratories Inc.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Latest IDXX
- EVP, CFO and Treasurer Emerson Andrew exercised 265 shares at a strike of $178.26 and covered exercise/tax liability with 86 shares, increasing direct ownership by 4% to 4,421 units (SEC Form 4)
- IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test
- SEC Form 10-Q filed by IDEXX Laboratories Inc.
- IDEXX Laboratories Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- IDEXX Laboratories Announces Second Quarter Results
- Director Hooley Joseph L was granted 49 shares, increasing direct ownership by 18% to 325 units (SEC Form 4)
- IDEXX Releases 2025 Corporate Responsibility Report, Highlighting Progress Against Its Goals
- IDEXX Laboratories to Release 2026 Second Quarter Financial Results
- Executive Vice President Fennell George converted options into 639 shares and covered exercise/tax liability with 284 shares, increasing direct ownership by 4% to 10,433 units (SEC Form 4)
- SEC Form SD filed by IDEXX Laboratories Inc.
Latest QCLS
- SEC Form 3 filed by new insider Fagan Charles Todd
- SEC Form 10-Q filed by Q/C Technologies Inc.
- Q/C Technologies Appoints Veteran Silicon Photonics Engineer Yossef Ehrlichman as Founding Manager, Photonic Integrated Circuit (PIC) Development
- Q/C Technologies Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Other Events
- Q/C Technologies Relocates Headquarters to San Francisco in Proximity to World-Class Engineering Experts for Photonic Computing and Optical AI Inference Initiative
- SEC Form 10-Q filed by Q/C Technologies Inc.
- Director Voss Chelsea Sierra bought $5,522 worth of shares (1,753 units at $3.15) (SEC Form 4)
- Amendment: SEC Form 10-K/A filed by Q/C Technologies Inc.
- SEC Form 4 filed by White Billy Joe
- SEC Form 4 filed by Friscia Stephen